221 related articles for article (PubMed ID: 34618566)
1. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS.
Li C; Vides A; Kim D; Xue JY; Zhao Y; Lito P
Science; 2021 Oct; 374(6564):197-201. PubMed ID: 34618566
[TBL] [Abstract][Full Text] [Related]
2. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
[TBL] [Abstract][Full Text] [Related]
3. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.
Lito P; Solomon M; Li LS; Hansen R; Rosen N
Science; 2016 Feb; 351(6273):604-8. PubMed ID: 26841430
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic GTPase Activity of K-RAS Monitored by Native Mass Spectrometry.
Moghadamchargari Z; Huddleston J; Shirzadeh M; Zheng X; Clemmer DE; M Raushel F; Russell DH; Laganowsky A
Biochemistry; 2019 Aug; 58(31):3396-3405. PubMed ID: 31306575
[TBL] [Abstract][Full Text] [Related]
5. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by
Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE
J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681
[TBL] [Abstract][Full Text] [Related]
6. A spatial focusing model for G protein signals. Regulator of G protein signaling (RGS) protien-mediated kinetic scaffolding.
Zhong H; Wade SM; Woolf PJ; Linderman JJ; Traynor JR; Neubig RR
J Biol Chem; 2003 Feb; 278(9):7278-84. PubMed ID: 12446706
[TBL] [Abstract][Full Text] [Related]
7. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.
Yin G; Kistler S; George SD; Kuhlmann N; Garvey L; Huynh M; Bagni RK; Lammers M; Der CJ; Campbell SL
J Biol Chem; 2017 Mar; 292(11):4446-4456. PubMed ID: 28154176
[TBL] [Abstract][Full Text] [Related]
8. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
[TBL] [Abstract][Full Text] [Related]
9. Gbetagamma inhibits Galpha GTPase-activating proteins by inhibition of Galpha-GTP binding during stimulation by receptor.
Tang W; Tu Y; Nayak SK; Woodson J; Jehl M; Ross EM
J Biol Chem; 2006 Feb; 281(8):4746-53. PubMed ID: 16407201
[TBL] [Abstract][Full Text] [Related]
10. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
11. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
[TBL] [Abstract][Full Text] [Related]
12. RGS3 is a GTPase-activating protein for g(ialpha) and g(qalpha) and a potent inhibitor of signaling by GTPase-deficient forms of g(qalpha) and g(11alpha).
Scheschonka A; Dessauer CW; Sinnarajah S; Chidiac P; Shi CS; Kehrl JH
Mol Pharmacol; 2000 Oct; 58(4):719-28. PubMed ID: 10999941
[TBL] [Abstract][Full Text] [Related]
13. KRAS
Lou K; Steri V; Ge AY; Hwang YC; Yogodzinski CH; Shkedi AR; Choi ALM; Mitchell DC; Swaney DL; Hann B; Gordan JD; Shokat KM; Gilbert LA
Sci Signal; 2019 May; 12(583):. PubMed ID: 31138768
[TBL] [Abstract][Full Text] [Related]
14. Role of glutamine-61 in the hydrolysis of GTP by p21H-ras: an experimental and theoretical study.
Frech M; Darden TA; Pedersen LG; Foley CK; Charifson PS; Anderson MW; Wittinghofer A
Biochemistry; 1994 Mar; 33(11):3237-44. PubMed ID: 8136358
[TBL] [Abstract][Full Text] [Related]
15. GTP hydrolysis mechanisms in ras p21 and in the ras-GAP complex studied by fluorescence measurements on tryptophan mutants.
Antonny B; Chardin P; Roux M; Chabre M
Biochemistry; 1991 Aug; 30(34):8287-95. PubMed ID: 1883817
[TBL] [Abstract][Full Text] [Related]
16. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
[TBL] [Abstract][Full Text] [Related]
17. KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation.
Lu J; Bera AK; Gondi S; Westover KD
Biochemistry; 2018 Jan; 57(3):324-333. PubMed ID: 29235861
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of GTP hydrolysis by p21N-ras catalyzed by GAP: studies with a fluorescent GTP analogue.
Moore KJ; Webb MR; Eccleston JF
Biochemistry; 1993 Jul; 32(29):7451-9. PubMed ID: 8338843
[TBL] [Abstract][Full Text] [Related]
19. Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down.
Hobbs GA; Wittinghofer A; Der CJ
Cancer Cell; 2016 Mar; 29(3):251-253. PubMed ID: 26977877
[TBL] [Abstract][Full Text] [Related]
20. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants.
Trahey M; McCormick F
Science; 1987 Oct; 238(4826):542-5. PubMed ID: 2821624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
